Aims: Leiomyosarcomas (LMS) are diverse rumours with different biological b
ehaviour. To evaluate the biological nature of intraabdominal and retroperi
toneal leiomyosarcomas we retrospectively examined the immunoreactivity of
p53, bcl-2 and proliferative activity expressed as Ki-67-labelling index in
43 tumours.
Methods: Immunohistochemical staining was performed using a peroxidase-stre
ptavidin method on paraffin-embedded sections using specific anti-p53, anti
-bcl-2 and anti Ki-67 monoclonal antibodies.
Results: Of 43 tumours, seven were located in the stomach, 11 in the small
or large bowel, 12 in the uterus, 11 in the retroperitoneum and two cases i
n the urinary bladder. Five-year disease-free survival was 46.5%. Twenty-th
ree patients (53.4%) died of the disease. Positive immunoreactivity for p53
and bcl-2 was found in 18 (41.9%) and 26 patients (60.5%), respectively. P
ositive Ki-67 staining was observed in eight patients (18.6%). Proliferativ
e indices were higher in LMS with high mitotic activity (P=0.004) and high
grade (P=0.009). All Ki-67 positive LMS were intermediate or high-grade tum
ours. Ki-67-labelling index showed inverse relationship to bcl-2 expression
. A trend towards higher survival and expression of bcl-2, p53 or Ki-67 was
found.
Conclusions: Our results demonstrate that p53 and bcl-2 are expressed in a
substantial number of intraabdominal and retroperitoneal leiomyosarcomas. I
n our study, the expression of these biomarkers did not predict patient out
come. Higher Ki-67 labelling indices were found in more biologically aggres
sive leiomyosarcomas. (C) 2001 Harcourt Publishers Ltd.